Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (March 2025)
11 slides from Syngene International's investor presentation, Mar 12, 2025
Slide 1: Stock exchange cover letter for Investor Presentation
Ref: Syn/CS/SE/IP/2024-25/Mar/06 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com March 12, 2025 To,
Slide 2: Syngene Investor Meet 12 March 2025
Syngene Putting Science to Work Investor Meet 12 March 2025
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: A Decade of Growth: Strengthening Infrastructure, Capabilities and Partnerships
A Decade of Growth: Strengthening Infrastructure, Capabilities and Partnerships Expanding capacity Building capabilities for future Building partnerships (in Million sq. ft.) (#) 2.2 8,146 (#) 400+ 0.9 3,526 250+ March’16 FY16 March’24 FY24 FY16 March’16 FY24 March’24 FY16 March’16 FY24 March’24 Mor
Slide 5: Strategic investments have pivoted Syngene to growth while maintaining business economics
Strategic investments have pivoted Syngene to growth while maintaining business economics over uncertain times and positioning for further future growth Continued investment for future growth Sustained revenue growth around mid teens Maintained EBITDA margin in high 20s Cumulative Gross Block Rs Mn
Slide 6: CRDMO – A multi billion-dollar market opportunity
CRDMO – A multi billion-dollar market opportunity Global CRDMO market ($ bn) is large and growing CRDMO market has exciting opportunities ahead with key tailwinds CRDMO market continues to outgrow the underlying pharma market* and offers Implications for opportunity for continued growth and value cr
Slide 7: Continue the journey of creating a future-fit Syngene
Continue the journey of creating a future-fit Syngene | Unpacking three pillars of the evolving business Business Well positioned to capture ..with key strategic levers ..focusing on near term ..and mid to long term drivers to the market opportunity.. in place actions accelerate growth • 30+ years o
Slide 8: Our focus is to enhance capabilities to meet evolving needs of customer base
Our focus is to enhance capabilities to meet evolving needs of customer base • Explore adjacent growth modalities including ADCs, Oligos, Peptides, C> • Continue to expand the breadth of our existing • Increase productivity, streamline operations, capabilities across modalities reduce downtime, an
Slide 9: Acquisition of Bayview site secures access to the US market
Acquisition of Bayview site secures access to the US market, supported by strong customer interest Growing Market (USD Bn) Overall investment of US$50Mn • US Biologics market growing at 10-12% CAGR, 22 • of which 70% of human health customers remain including acquisition cost of Access to US LATAM &
Slide 10: Summary
Summary Market opportunity remains CRDMO market is expected to reach $320 bn by 2030, with key tailwinds including China+1, IRA, increased strong and attractive outsourcing by pharma companies. Capitalizing from a position of strength, Syngene is well positioned to increase its market share with
Slide 11: For more details
For more details Visit our website www.syngeneintl.com https://twitter.com/SyngeneIntl https://www.linkedin.com/company/syngene-international-limited https://www.facebook.com/syngeneintl/ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Krishnan G/ Nandini Agarwal
Syngene International — Investor Presentation (March 2025) on 6ix